These findings indicate the therapeutic efficacy of AdFITC-CAR T-cells in combination with CD117 Db-FM against healthy CD117-expressing cells in vivo, supporting the potential use of this approach to not only target AML cells, but also to reduce in a time-dependent manner healthy HSPCs as a pre-conditioning regimen prior to healthy HSPC transplantation. Here, KIT is linked to acute myeloid leukemia.